v-Src oncogene induces Trop2 proteolytic activation via cyclin D1

Cancer Research

Volumn 76, Issue 22, 2016, Pages 6723-6734

  Ju, Xiaoming ^a,b   Jiao, Xuanmao ^a,b   Ertel, Adam ^a,b   Casimiro, Mathew C ^a,b   Di Sante, Gabriele ^a,b   Deng, Shengqiong ^a,b   Li, Zhiping ^a,b   Di Rocco, Agnese ^a,b   Zhan, Tingting ^a,b   Hawkins, Adam ^a,b   Stoyanova, Tanya ^c,g   Andò, Sebastiano ^d   Fatatis, Alessandro ^b,e   Lisanti, Michael P ^b,f,h   Gomella, Leonard G ^a,b   Languino, Lucia R ^a,b   Pestell, Richard G ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALABRIA   (Italy)

^e DREXEL UNIVERSITY   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g STANFORD UNIVERSITY   (United States)

^h UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; GAMMA SECRETASE; TUMOR ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; TUMOR MARKER; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; PROTEIN TYROSINE KINASE; TROP2 PROTEIN, MOUSE; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CELL SELF-RENEWAL; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME SUBSTRATE COMPLEX; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ONCOGENE SRC; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROSTATE CELL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RECURRENCE FREE SURVIVAL; UPREGULATION; ANIMAL; GENETIC TRANSFECTION; GENETICS; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CYCLIN D1; HUMANS; MICE; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES; TRANSFECTION;

EID: 84995467881     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-3327     Document Type: Article

References (43)

1. Ju X, Casimiro MC, Gormley M, Meng H, Jiao X, Katiyar S, et al. Identification of a cyclin D1 network in prostate cancer that antagonizes epithelial-mesenchymal restraint. Cancer Res 2014;74:508-19.
2. Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines GKIII, et al. pp60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 1999;274:7341-50.
3. Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, et al. Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 2000;20:672-83.
4. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature 2001;411:1017-21.
5. Hulit J, Wang C, Li Z, Albanese C, Rao M, Di Vizio D, et al. Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 2004;24:7598-611.
6. Kraus S, Gioeli D, Vomastek T, Gordon V, Weber MJ. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 2006;66:11047-54.
7. Cai H, BabicI, Wei X, Huang J, Witte ON. Invasive prostate carcinoma driven by c-Src and androgen receptor synergy. Cancer Res 2011;71:862-72.
8. Drake JM, Graham NA, Lee JK, Stoyanova T, Faltermeier CM, Sud S, et al. Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets. Proc Natl Acad Sci U S A 2013;110:E4762-9.
9. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol 2012;44:2144-51.
10. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011;121:3804-9.
11. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A 2008;105:20882-7.
12. Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer 2015;6:84-105.
13. Guerra E, Trerotola M, Dell' Arciprete R, Bonasera V, Palombo B, El-Sewedy T, et al. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res 2008;68:8113-21.
14. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-63.
15. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96:417-23.
16. Trerotola M, Ganguly KK, Fazli L, Fedele C, Lu H, Dutta A, et al. Trop-2 is upregulated in invasive prostate cancer and displaces FAK from focal contacts. Oncotarget 2015;6:14318-28.
17. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J, Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev 2012;26:2271-85.
18. Ju X, Ertel A, Casimiro MC, Yu Z, Meng H, McCue PA, et al. Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures. Cancer Res 2013;73:978-89.
19. Lindsay J, Jiao X, Sakamaki T, Casimiro MC, Shirley LA, Tran TH, et al. ErbB2 induces Notch1 activity and function in breast cancer cells. Clin Transl Sci 2008;1:107-15.
20. Rao M, Casimiro MC, Lisanti MP, D'Amico M, Wang C, Shirley LA, et al. Inhibition of cyclin D1 gene transcription by Brg-1. Cell Cycle 2008;7:647-55.
21. Jiao X, Katiyar S, Willmarth NE, Liu M, Ma X, Flomenberg N, et al. c-Jun induces mammary epithelial cellular invasion and breast cancer stem cell expansion. J Biol Chem 2010;285:8218-26.
22. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, et al. p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression invivo. Proc Natl Acad Sci U S A 2009;106:19035-9.
23. Wu K, Jiao X, Li Z, Katiyar S, Casimiro MC, Yang W, et al. Cell fate determination factor Dachshund reprograms breast cancer stem cell function. J Biol Chem 2011;286:2132-42.
24. Jiao X, Rizvanov AA, Cristofanilli M, Miftakhova RR, Pestell RG. Breast cancer stem cell isolation. Methods Mol Biol 2016;1406:121-35.
25. Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, et al. Gene expression profiling of human prostate cancer stem cells reveals a proinflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol 2008;9:R83.
26. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
27. Dennis GJr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 2003;4:P3.
28. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25-9.
29. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science 2010;329:568-71.
30. Brown MS, Ye J, Rawson RB, Goldstein JL. Regulated intramembrane proteolysis: a control mechanism conserved from bacteria to humans. Cell 2000;100:391-8.
31. Pellacani D, Oldridge EE, Collins AT, Maitland NJ. Prominin-1 (CD133) expression in the prostate and prostate cancer: a marker for quiescent stem cells. Adv Exp Med Biol 2013;777:167-84.
32. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008;68:9703-11.
33. Smith BA, Sokolov A, Uzunangelov V, Baertsch R, Newton Y, Graim K, et al. A basal stem cell signature identifies aggressive prostate cancer phenotypes. Proc Natl Acad Sci U S A 2015;112:E6544-52.
34. Bourguignon LY, Peyrollier K, Xia W, Gilad E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem 2008;283:17635-51.
35. Goldstein AS, Witte ON. Does the microenvironment influence the cell types of origin for prostate cancer? Genes Dev 2013;27:1539-44.
36. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.
37. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001;114:3865-72.
38. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117:3539-45.
39. Berry PA, Maitland NJ, Collins AT. Androgen receptor signalling in prostate: effects of stromal factors on normal and cancer stem cells. Mol Cell Endocrinol 2008;288:30-7.
40. Casimiro MC, Wang C, Li Z, Di Sante G, Willmart NE, Addya S, et al. Cyclin D1 determines estrogen signaling in the mammary gland invivo. Mol Endocrinol 2013;27:1415-28.
41. Allenspach EJ, Maillard M, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Ther 2002;1:466-76.
42. Stahl M, Ge C, Shi S, Pestell RG, Stanley P. Notch1-induced transformation of RKE-1 cells requires up-regulation of cyclin D1. Cancer Res 2006;66:7562-70.
43. Ding Z, Wu CJ, Chu GC, Xiao Y, Ho D, Zhang J, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011;470:269-73.